London, Jul 29 (AP) The European Commission says it signed a 63 million euro (USD 72 million) deal to secure thousands of doses of remdesavir, the only licensed experimental drug to treat people with severe COVID-19.

The European Commission says it had bought enough remdesivir, sold by Gilead Sciences as Veklury, to treat about 30,000 patients with serious coronavirus illness for member countries and the United Kingdom.

Also Read | ICMR to Conduct the International Symposium on Novel Ideas in Science and Ethics of Vaccines Against COVID-19 Pandemic on July 30: Live News Breaking And Coronavirus Updates on July 29, 2020.

This month, the U.S. announced it had signed a deal with Gilead to buy nearly all of the company's production of the drug through September.

Numerous public health experts slammed the agreement, calling the U.S. move selfish and warned other countries could lose out. (AP)

Also Read | Kodak Shares Surge 1900% in Two Days After Former Camera Maker Secures $765 Million US Govt Loan to Produce Generic Drug Amid COVID-19 Pandemic.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)